Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

The study will be conducted across multiple European centres to assess the safety and tolerability of multiple doses of AZD2171 in patients with AML.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leukaemia Acute Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Myelocytic Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provision of written informed consent
Male/female, 18 yrs or over
WHO performance status 0-2
Disease not responding to or relapsing after chemotherapy or elderly patients not suited to chemotherapy

Exclusion criteria

Acute myeloid leukaemia arising from previous chronic myeloid leukaemia or acute myeloid leukaemia of type FAB M3
Previous treatment against new blood vessel formation (anti-angiogenic)
Chest X-ray showing leukaemia in the lungs

Treatment and study plan

AZD2171

Drug

Primary outcomes

The primary objective is to determine the safety and tolerability of multiple oral doses of AZD2171 in AML patients by assessment of AEs, BP&pulse, heart rate respiration rate, EKG, clinical chemistry

Secondary outcomes

Efficacy, PK

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start: 2004
First posted: Jul 17, 2007
Registry last updated: Jan 21, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed